Italian luxury group Zegna names Tagliabue as new group CEO-July 2024-www.financetom.com

Italian luxury group Zegna names Tagliabue as new group CEO

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Italian luxury group Zegna names Tagliabue as new group CEO

Nov 24, 2025 3:55 AM

Nov 24 (Reuters) - Italian luxury group Ermenegildo

Zegna ( ZGN ) on Monday named Gianluca Tagliabue as its

new CEO, effective January 1. Tagliabue is currently the group's

finance chief.

The company also named Edoardo and Angelo Zegna, members of

the fourth generation of the Zegna family, as co-chief executive

officers of the Zegna brand.

Previous page： Buckle Insider Sold Shares Worth $854,496, According to a Recent SEC Filing Next page： Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Buckle Insider Sold Shares Worth $854,496, According to a Recent SEC Filing

Sep 13, 2024

11:08 AM EDT, 09/12/2024 (MT Newswires) -- Dennis H Nelson, Director, President & CEO, on September 10, 2024, sold 20,453 shares in Buckle (BKE) for $854,496. Following the Form 4 filing with the SEC, Nelson has control over a total of 2,310,552 shares of the company, with 324,000 shares held directly and 1,986,552 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/885245/000088524524000087/xslF345X05/wk-form4_1726153070.xml Price: 41.56,...

Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall

Sep 13, 2024

11:13 AM EDT, 09/12/2024 (MT Newswires) -- Oncternal Therapeutics' ( ONCT ) shares sank 58% in recent Thursday trading after the company said it has decided to discontinue its clinical studies and explore strategic alternatives. The company also said it will discontinue all product development activities, lay off some staff, and implement other cost-cutting measures while exploring alternatives, which may...

Update: Moderna Shares Fall After Cutting Annual R&D Spending by $1.1 Billion From 2027

Sep 13, 2024

11:09 AM EDT, 09/12/2024 (MT Newswires) -- (Updates with the latest stock movement in the headline and the first paragraph.) Moderna ( MRNA ) shares fell more than 18% in recent Thursday trading after the company said it is reducing its annual R&D expense by about $1.1 billion starting in 2027 in light of recent commercial challenges. The company now...

--Street Color: US FDA Authorizes Over-the-Counter Hearing Aid Software for Apple's AirPods Pro

Sep 13, 2024

11:09 AM EDT, 09/12/2024 (MT Newswires) -- Price: 222.76, Change: +0.10, Percent Change: +0.04 ...